Phase Forward to Lead Sessions at CDISC Interchange Japan 2010

TOKYO--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate at CDISC Interchange Japan 2010, July 20-23 at the Toshi Center Hotel in Tokyo.

“Simplifying Trial Data Extraction with CDISC ODM as a Web Service Interface”

At CDISC Interchange Japan, company representatives will lead four sessions on key industry data standards and drug safety related issues:

Who: Robbert P. van Manen, Senior Technical Solutions Consultant, Phase Forward

What: “Define.XML - It’s Not Just for Submissions Any More”

When: Tuesday, July 20, 3:30 – 5:00 p.m. JST (Japan Standard Time)

Who: Robbert P. van Manen, Senior Technical Solutions Consultant, Phase Forward

What: “Doing More with SDTM – Safety Signal Detection on Clinical Trial Data”

When: Wednesday, July 21, 9:00 – 10:45 a.m. JST

Who: Joerg Dillert, Principal Consultant, Phase Forward

What: “E2B under the Umbrella of HL7 and BRIDG: Looking To the Future of Data Integrations between Pharmacovigilance (E2B) and Clinical Data Management”

When: Wednesday, July 21, 9:00 – 10:45 a.m. JST

Who: Herve Ouambo, Principal Technical Consultant, Phase Forward

What: “Simplifying Trial Data Extraction with CDISC ODM as a Web Service Interface”

When: Wednesday, July 21, 3:45 – 4:45 p.m. JST

Phase Forward will also be exhibiting booth #7 at the CDISC Interchange Japan 2010. Members of the media interested in speaking with Phase Forward should contact Maria Sumner at [phone] or [e-mail] or Juli Greenwood at 781-672-3137 or [e-mail].

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.